[Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?]

Area of Science:

• Biochemistry and Molecular Biology
• Cardiovascular Medicine
• Inflammation Research

Context:

• Classic risk assessment for cardiocerebrovascular diseases explains only 50% of risk variability.
• Inflammatory processes significantly contribute to endothelial dysfunction and atherosclerotic plaque rupture.
• Novel biomarkers are needed to improve risk prediction beyond traditional factors.

Purpose:

• To highlight the significance of lipoprotein-associated phospholipase A2 (Lp-PLA2) as a biomarker for cardiocerebrovascular disease risk.
• To elucidate the role of Lp-PLA2 in atherosclerotic plaque formation, progression, and instability.
• To emphasize Lp-PLA2's value in patient risk stratification and guiding treatment intensity.

Summary:

• Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a specific marker of vascular inflammation, directly involved in atherosclerotic plaque pathogenesis.
• Elevated Lp-PLA2 concentrations correlate with increased risk of cardiocerebrovascular events and are associated with unstable plaques.
• Lp-PLA2 is a stable, independent predictor complementary to high-sensitivity C-reactive protein (hs-CRP), aiding in risk stratification, especially in metabolic syndrome patients.

Impact:

• Lp-PLA2 determination improves patient risk stratification, enabling tailored treatment strategies for cardiocerebrovascular diseases.
• Inhibition of Lp-PLA2 is linked to reduced cytokines and improved plaque stability.
• Lipid-modifying drugs reduce Lp-PLA2 levels, decreasing cardiocerebrovascular event frequency and supporting aggressive LDL-cholesterol lowering targets.